Proactiveinvestors news media have interviewed Imagion Biosystems CEO Bob Proulx, who answers questions about the company’s early cancer detection technology, its place in the the medical imaging market, intellectual property protections, and more.
Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent
January 31, 2026
Imagion Biosystems Hits Major Milestone, Submits IND Application to U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent Key Highlights: Imagion Biosystems has